(¿Â¶óÀÎ) Á¦ 54ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãá°èÇмú´ëȸ : 2021-05-21±³À°ÀÏÀÚ : 2021-05-21
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) Á¦ 54ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãá°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : Á¤º°
¿¬¶ôó : 02-565-3350
À̸ÞÀÏ :
ksh@koreanhypertension.org ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, ½Å°æ°ú, °¡Á¤ÀÇÇаú»ý¸®ÇÐ, ¾à¸®ÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 18 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í *µî·Ïºñ: »çÀüµî·Ï-±³¼ö ¹× °³¿øÀÇ 3¸¸¿ø / ÀüÀÓÀÇ, Àü°øÀÇ ±âŸ 1.5¸¸¿ø / 65¼¼ÀÌ»ó Á¤È¸¿ø, Çлý(¹«·á) *ÇöÀåµî·ÏÀº ¾øÀ½.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-21 Rooom A 09:45~10:00 µ¿¸Æ°æÁ÷µµÀÇ °³³ä Á¤Çý¹®(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 10:00~10:15 µ¿¸Æ°æÁ÷µµÀÇ ÃøÁ¤ ¹æ¹ý ÃÖÀçÇõ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 10:15~10:30 µ¿¸Æ°æÁ÷µµ¸¦ È°¿ëÇÑ ½É³úÇ÷°ü ÁúȯÀÇ Áø´Ü ¹ÚÁø¼±(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 10:30~10:45 µ¿¸Æ°æÁ÷µµ¸¦ È°¿ëÇÑ ½É³úÇ÷°ü ÁúȯÀÇ ¿¹ÈÄ ¿¹Ãø ±èÇзÉ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 09:45~10:00 ÀþÀº °íÇ÷¾Ð ȯÀÚ ÇöȲ: À¯º´·ü, ÀÎÁöÀ², Ä¡·áÀ², ÀþÀº °íÇ÷¾Ð ȯÀÚ ±ÞÁõÀÇ ¿øÀÎ, ÀÎÁöÀ² ¹× Ä¡·áÀ²ÀÌ ³·Àº ÀÌÀ¯ ±èÇý¹Ì(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 10:00~10:15 ÀþÀº °íÇ÷¾Ð ȯÀÚÀÇ Æ¯Â¡°ú ¹®Á¦Á¡: ÀþÀº °íÇ÷¾Ð ȯÀÚÀÇ ÀÓ»óÀû Ư¡, °íÇ÷¾Ð ÇÕº´Áõ ¹ß»ý·ü, Ç÷¾Ð Á¶ÀýÀ» ¼ÒȦÈ÷ ÇÏ¿´À» ¶§ÀÇ ¹®Á¦Á¡ Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 10:15~10:30 ÀþÀº °íÇ÷¾Ð ȯÀÚÀÇ Ä¡·á ¹æ¹ý: »ýÈ°¿ä¹ý ¹× ¾à¹° Ä¡·á(¾î¶°ÇÑ ¾àÁ¦°¡ ¼±È£ µÇ´ÂÁö Æ÷ÇÔ) Á¶µ¿Çõ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 10:30~10:45 ÀþÀº °íÇ÷¾Ð ȯÀÚÀÇ ÀÎÁöÀ² ¹× Ä¡·áÀ²À» ³ôÀ̱â À§ÇÑ ¹æ¾È ±èÇöÁø(ÇѾçÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 09:45~10:00 ±¹³» Æó°íÇ÷¾Ð °ø´Ü ºòµ¥ÀÌÅÍ ºÐ¼®, 2004-2018 À念¿ì(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 10:00~10:15 Çѱ¹Çü Æó°íÇ÷¾Ð Áø·áÁöħ ¹ÚÀçÇü(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 10:15~10:30 Æó°íÇ÷¾Ð Á¶ÀýÀ» À§ÇÑ »ýÈ° ½À°ü °ü¸® ³ª½Â¿ø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 10:30~10:45 Æó°íÇ÷¾Ð ȯÀÚ¿¡¼ÀÇ ¿ÏÈ ÀÇ·á ÀÌÁÖÈñ(ÃæºÏÀÇ´ë)
Åä·Ð 05-21 Rooom C 10:45~11:00 Åä·Ð ±è±â¹ü À̼ö¿ë ÀÌâÈÆ(¼¿ïÀÇ´ë ºÎ»êÀÇ´ë ¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 11:10~11:25 Impact of COVID-19 on BP control °ø¹Î±Ô(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 11:25~11:40 Impact of COVID-19 on hypertensive complications ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 11:40~11:55 COVID-19 vaccination Basic concept ±âÇö±Õ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 11:55~12:10 COVID-19 vaccination and cardiovasular complications Á¶À翵(Àü³²ÀÇ´ë)
Åä·Ð 05-21 Rooom A 12:10~12:25 Åä·Ð ±è¼ºÇØ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 11:10~11:25 Comparison of domestic and oversea guidelines on hypertensive complication screening À̼±±â(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 11:25~11:40 Dyslipidemia in Hypertension Why and How to deal ? ¼ÕÁ¤¿ì(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 11:40~11:55 ECG abnormality Why and How to deal ? ±è¹ü¼º(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 11:55~12:10 Abnoraml U/A : Why and How to deal ? ÃÖÀÚ¿¬(°í·ÁÀÇ´ë)
Åä·Ð 05-21 Rooom B 12:10~12:25 Åä·Ð ±èÀÀÁÖ ½Å¹Ì½Â ÃÖ¼ºÈÆ ÇѼº¿ì(°í·ÁÀÇ´ë °¡ÃµÀÇ´ë ÇѸ²ÀÇ´ë ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 11:10~11:25 Association of Blood Pressure With the Progression of CKD ÀÌÁö¿µ(Àû½ÊÀÚº´¿ø)
±³À°½Ã°£ 05-21 Rooom C 11:25~11:40 Optimal blood pressure for patients with CKD ÀÌÀ¯ºó(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 11:40~11:55 Ambulatory blood pressure monitoring guided antihypertensive treatment ±èÀ±¹Ì(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 11:55~12:10 Cardiovascular or mortality risk of controlled hypertension and importance of physical activity, Heart 2021 ¹Ú¼¼ÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 12:35~13:25 Luncheon Symposium I ½ÅÁøÈ£(ÇѾçÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 12:35~13:25 Luncheon Symposium II ±èÇзÉ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 12:35~13:25 Luncheon Symposium III ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 13:35~13:50 ÄڷγªÆÒµ¥¹Í¿¡¼ ½ÅüȰµ¿ ½ÇõÀÇ À§±â ÀÌ¿Â(½ºÆ÷Ã÷Á¤Ã¥°úÇпø)
±³À°½Ã°£ 05-21 Rooom A 13:50~14:05 ÄڷγªÆÒµ¥¹Í¿¡¼ ½ÅüȰµ¿ ½Çõ±Ç°í¾È(¸¶½ºÅ© Âø¿ë½Ã ¿îµ¿ Æ÷ÇÔ) ±è¿ëȯ(°¸ª¿øÁÖ´ëÇб³)
±³À°½Ã°£ 05-21 Rooom A 14:05~14:20 ´Ù¾çÇÑ È¨Æ®·¹ÀÌ´× ½Çõ¹æ¹ý ÀÌÁø¼®(½ºÆ÷Ã÷Á¤Ã¥°úÇпø)
±³À°½Ã°£ 05-21 Rooom A 14:20~14:35 µðÁöÅÐ Ä¡·á±â¼úÀ» È°¿ëÇÑ ¿îµ¿ ÁßÀç Àü·« ¹ÚÇöÅÂ(µ¿¾Æ´ëÇб³)
±³À°½Ã°£ 05-21 Rooom B 13:35~13:50 The importance of healthy diets in hypertensive patients ½Åµ¿Çõ(°³² ¸ÞÀÌÀúº´¿ø)
±³À°½Ã°£ 05-21 Rooom B 13:50~14:05 Mineral supplements Àü°æÇö(±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø)
±³À°½Ã°£ 05-21 Rooom B 14:05~14:20 Vitamin supplements ±è¹üÅÃ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 14:20~14:35 Omega-3 fatty acid supplements ±ÇÀ¯Áø(¿¬¼¼ÀÇ´ë)
Åä·Ð 05-21 Rooom B 14:35~14:50 Åä·Ð ±èº´±Ô ±èÈ¿Àº ÀÌÁÖ¹Ì(ÀÎÁ¦ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø À»ÁöÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 13:35~13:50 Blood pressure variability and CVD disease ±èÇзÉ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 13:50~14:05 Glucose variability and CVD disease Á¤ÂùÈñ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 14:05~14:20 Wearable technology in CVD disease Àü±âÇö(¸ÞµðÇ÷º½º ¼¼Á¾º´¿ø)
Åä·Ð 05-21 Rooom C 14:20~14:35 Åä·Ð ±è°æ¼ö ¼¿ø¿ì ¼Àçºó È«ÁØÈ(Â÷ÀÇ´ë ÇѸ²ÀÇ´ë ¼¿ïÀÇ´ë À»ÁöÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 15:00~15:15 Coenzyme Q10 ¹Ú»ó¹Î(À»ÁöÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 15:15~15:30 Arginine ±èÀÎö(°è¸íÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 15:30~15:45 ³ë´Ï, ºñÆ® ÁÖ½º ½ÅÁ¤ÈÆ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 15:45~16:00 Herbal medication: ¾çÆÄÁóÀ̳ª ²®Áú´Ù¸°¹°, ¹Îµé·¹Áó¡¦ ÀÌÁÖÈñ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 15:00~15:15 Familial associations of blood pressure and BMI Àå¼À±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 15:15~15:30 Secular trends of blood pressure and BMI and their associations in children and adolescents ±èÅÂÁ¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 15:30~15:45 Environmental exposure and drug induced hypertension in in children and adolescents ½ÅÀçÀÏ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 15:45~16:00 Prematurity and hypertension °ûÁöÈñ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 15:00~15:15 The impact of intensive blood pressure control for cognitive function ÀÓ»óÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 15:15~15:30 The impact of intensive blood pressure control for small vessel disease ±èÁÖÇÑ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 15:30~15:45 The blood pressure control strategy for the stroke survivors (ÀÓ»ó Áø·á Àû¿ë) Á¤¿íÁø(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 15:45~16:00 The blood pressure control strategy for the patients with Parkinsonism (ÀÓ»ó Áø·á Àû¿ë) Á¶ÀºÁÖ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 16:25~16:40 Aminopeptidase A inhibitor ±èÇüÀ±(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 16:40~16:55 SGLT2 for treatment of hypertension À̼ö¿ë(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 16:55~17:05 ARNI for treatment of hypertension ÃÖÈ«¹Ì(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom A 17:05~17:20 Orlistat for treatment of obesity and hypertension ¼ÕÀå¿ø(°¡Å縯ÀÇ´ë)
Åä·Ð 05-21 Rooom A 17:20~17:35 Åä·Ð Á¶Á¤¼±(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 16:25~16:40 Cardiovascular risk of isolated systolic or diastolic hypertension in young adults ÀÌÈ£±Ô(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom B 16:40~16:55 Factors associated with hypertension management in young adults Àü¿ë¿ì(´ëÇÑ»ê¾÷º¸°ÇÇùȸ)
±³À°½Ã°£ 05-21 Rooom B 16:55~17:05 Age and sex specifc target of blood pressure for CVD prevention ±èÇü·¡(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 16:25~16:40 Korean Hypertension Cohort ¼Ò°³ ÀÌÇØ¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-21 Rooom C 16:40~16:55 °íÇ÷¾Ð ¿¬±¸¿¡¼ °øÀÍÀû ºòµ¥ÀÌÅÍÀÇ Çʿ伺 ÀÌÁÖ¿¬(¼¿ï´ëÇб³ ¾àÇдëÇÐ)
±³À°½Ã°£ 05-21 Rooom C 16:55~17:05 À¯°ü±â°ü °øµ¿¿¬±¸½ÉÀÇÀ§¿øȸ ±¸¼º Á¦¾È ±è±¤ÀÏ(¼¿ïÀÇ´ë)
Åä·Ð 05-21 Rooom C 17:05~17:20 Åä·Ð ±èµ¿¿í ¹éÁø°æ ÀÌÀåÈÆ(±¹¹Î°Ç°º¸Çè°ø´Ü NECA °æºÏÀÇ´ë)